La molécula que combate la obesidad y ahora promete revolucionar el tratamiento de la apnea del sueño – ELTIEMPO.COM
Recent clinical trials have identified that tirzepatide, a dual-action molecule primarily used for weight management and type 2 diabetes, significantly reduces the severity of obstructive sleep apnea (OSA) in adults with obesity. Published findings in the New England Journal of Medicine indicate that participants treated with the medication experienced a substantial decrease in the number … Read more
